Recombinant protein maker rEVO Biologics files for a $75 million IPO
rEVO Biologics, which markets a recombinant protein that
prevents blood clots in patients with a rare disorder, filed on
Wednesday with the SEC to raise up to $75 million in an initial
public offering. The company was originally formed as a
subsidiary of Genzyme and completed an IPO in 2002, before it was
bought by French pharmaceutical company LFB Biotechnologies in
The Framingham, MA-based company, which was founded in 1993 and booked $33 million in sales for the 12 months ended March 31, 2014, plans to list on the NASDAQ under the symbol RBIO. rEVO Biologics initially filed confidentially on April 11, 2014. Piper Jaffray and Guggenheim Securities are the joint bookrunners on the deal. No pricing terms were disclosed.